HHUA 人子宮內(nèi)膜癌細(xì)胞
Catalogue No.: C1310
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%EMEM(MEM+NEAA)+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

However, most immune-pkdiated adverse events (including grade 3-4 adverse events) can be managed by using published managepknt algorithms without permanent discontinuation of the agent. As nivolumab and pembrolizumab enter the clinic, and with more PD-1 pathway agents in